Sector News

Roche CEO attacks Britain’s ‘stupid’ cancer drug system

September 9, 2015
Life sciences

(Reuters) – Roche Chief Executive Severin Schwan criticized Britain’s health system on Tuesday after two of the company’s cancer drugs were dropped from use, calling it a “stupid” way to control costs that could jeopardize research in the country.

He also criticized India, an emerging economic powerhouse, for not doing more to increase its spending on healthcare.

Roche, as the world’s biggest maker of cancer drugs, has had frequent run-ins with Britain over its system for curbing use of medicines that are not considered cost effective.

The latest clash came on Friday, when a government fund that helps patients receive cancer drugs not routinely paid for by the National Health Service said it would no longer pay for a number of medicines.

The Swiss drugmaker’s Avastin for certain cancers and Kadcyla for breast cancer were among products “de-listed” by the Cancer Drugs Fund (CDF).

Schwan said the decision failed to recognize the value such medicines offered society by keeping patients out of hospital and allowing them to remain productively employed.

“It’s stupid from a cost point of view not to look at the overall cost of healthcare,” he told a media briefing.

“This is really sad for patients and I have no understanding for this decision whatsoever … there is a fundamental flaw in how the UK operates when it comes to pricing for medicine.”

The CDF, defending the cuts last week, said it had to make difficult choices but that it was its duty to ensure maximum value for money.

Schwan said there would be also knock-on effects for research in Britain, since if drugs like Avastin were not available as standard then Roche would not be able to do certain clinical trials in the country.

“Eventually, this will hurt us on the research side in the UK. This is just a bad decision, not only for patients but also for society as a whole,” Schwan said.

Britain’s pharmaceuticals industry also complained this week about the country’s slow adoption of new medicines in clinical practice, although drug companies also face hurdles in getting the latest drugs prescribed in other European markets.

The Roche boss had harsh words for India, too, saying the country was not spending enough as a percentage of its gross domestic product on healthcare, estimating it at only about 1 percent to 2 percent.

He said that salvos targeting drug companies over the high cost of medicines in developing countries were distractions from this more important issue.

“You have a real lack of healthcare infrastructure which doesn’t even enable generic companies to bring medicines to the Indian population,” Schwan said.

By John Miller (Additional reporting by Ben Hirschler; Editing by Pravin Char)

comments closed

Related News

November 21, 2021

Johnson & Johnson to focus on pharmaceuticals

Life sciences

Johnson & Johnson has announced that it plans to separate its Consumer Health business, leaving the new Johnson & Johnson to focus on pharmaceuticals and medical devices. Alex Gorsky, current CEO, will become the Executive Chairman of the new Johnson & Johnson. Joaquin Duato, currently Vice Chairman of the Company’s Executive Committee, will become the new CEO.

November 21, 2021

Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform

Life sciences

Novo Nordisk today announced that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna). The acquisition of Dicerna’s ribonucleic acid interference (RNAi) platform is a strategic addition to Novo Nordisk’s existing research technology platforms and supports the strategy of using a broad range of technology platforms applicable across all Novo Nordisk’s therapeutic focus areas.

November 21, 2021

What are the benefits of the digital health revolution?

Life sciences

Naomi predicts that start-ups will continue to take over the healthcare industry, and Big Pharma companies will be forced to adapt to the future by partnering with small tech start-ups, or fade away due to irrelevance. Discover more of industry leader Naomi Fried’s insights as she discusses the future of healthcare with Andrew Kris of Borderless

Send this to a friend